Literature DB >> 33619162

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE).

Daniel J Wallace1, Florence Figueras2, William A Wegener3, David M Goldenberg3.   

Abstract

Entities:  

Keywords:  biological therapy; cytokines; lupus erythematosus; systemic

Year:  2021        PMID： 33619162     DOI： 10.1136/annrheumdis-2020-219803

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

Review 1.  Deep Insight into the Role of MIF in Spondyloarthritis.

Authors:  Brian Wu; Akihiro Nakamura
Journal:  Curr Rheumatol Rep       Date:  2022-07-09       Impact factor: 4.686

2.  Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  J Immunol       Date:  2022-04-27       Impact factor: 5.426

3.  Identification of novel tumor microenvironment-associated genes in gastric cancer based on single-cell RNA-sequencing datasets.

Authors:  Xujin Wei; Jie Liu; Zhijun Hong; Xin Chen; Kang Wang; Jianchun Cai
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.